FDA lawyer explains reasoning behind size of penalty in landmark Abbott consent decree
This article was originally published in Clinica
Executive Summary
The US FDA intended to send a message to other companies when it decided to impose a steep penalty on Abbott Laboratories, according to one of the US lawyers who worked on the case.